Skip to main content

Table 3 Dosing scheme per product used in the analysis

From: Budget impact analysis of ustekinumab in the management of moderate to severe psoriasis in Greece

Agent Dosing scheme
Adalimumab 80 mg at week 0, 40 mg at week 1, then 40 mg every other week
Etanercept 50 mg twice weekly for 12 weeks, then 50 mg once weekly
Infliximab 5 mg/kg at weeks 0, 2, and 6, then every 8 weeks
Ustekinumab 45 mg at weeks 0 and 4, then every 12 weeks